Psilocybin May Protect Nerves From Chemotherapy

The Mushroom Just Left the Therapist’s Office:

A psychedelic compound famous for changing the mind is suddenly being studied for something much more physical: keeping nerve cells alive.

By Gram Kracker | SykoActive — “Experience The Trip.”

There is a strange habit in modern culture: we decide what a thing is long before science finishes figuring out what that thing can do.

Cannabis was “weed.” Then researchers found an endocannabinoid system woven through human physiology.

Ketamine was an anesthetic, then a club drug, then—under controlled medical use—a rapid-acting intervention in treatment-resistant depression.

Psilocybin has spent decades trapped inside another cultural box: hallucinogen. Magic mushrooms. Psychedelic therapy. Mystical experiences. Depression studies. The smiling mushroom on the festival shirt your uncle probably should have thrown away in 1978.

But this week, something genuinely unusual happened.

Researchers at The University of Texas MD Anderson Cancer Center reported in Science that psilocybin prevented chemotherapy-induced peripheral nerve injury across several preclinical models. The compound preserved sensory nerve endings, protected touch sensation, reduced hypersensitivity and—perhaps most intriguingly—appeared to do it by keeping mitochondria moving through nerve fibers so the cells continued receiving energy. UT MD Anderson

And then came the part that should make even psychedelic skeptics raise an eyebrow:

A non-hallucinogenic compound targeting the same receptor pathway produced similar neuroprotection. UT MD Anderson

Read that again.

The trip might not be the entire medicine.

That doesn’t mean psychedelic experiences are irrelevant. It certainly does not mean people undergoing chemotherapy should start self-medicating with mushrooms. The work is preclinical, mainly involving animal models, and human efficacy has not been established.

But scientifically?

This is exactly the kind of result that blows a hole in our comfortable categories.

Welcome to today's Blogger Paper.

The blotter has officially escaped the brain.

CATEGORY: PSYCHEDELIC SCIENCE

The Story Hiding Behind the Psychedelic Renaissance

Most public conversation about psychedelics has revolved around psychiatric disorders: depression, PTSD, addiction, existential distress and anxiety associated with serious illness.

That makes sense. The modern revival of psychedelic medicine grew largely from psychiatry and neuroscience.

But the MD Anderson findings suggest the pharmacology of psychedelics may extend considerably further into peripheral physiology.

The study, published September 3, 2026, investigated chemotherapy-induced peripheral neuropathy, commonly abbreviated CIPN.

This condition can involve burning pain, numbness, tingling, cold sensitivity and loss of sensation in the hands and feet. For some people receiving cancer treatment, neuropathy becomes severe enough that oncologists must reduce or discontinue chemotherapy. Damage can also persist long after cancer treatment ends. UT MD Anderson

That is an ugly bargain:

Kill the cancer.

Damage the nerves.

Save the life.

Potentially impair the life you just saved.

Medicine sometimes operates in brutal trade-offs because biology does not negotiate like a used-car salesman.

The MD Anderson team approached the problem differently.

Instead of asking:

How do we reduce neuropathic pain after nerve injury occurs?

They asked something closer to:

Can we prevent the nerve from getting injured in the first place?

That distinction is enormous.

Two Doses. Before Chemotherapy.

Across preclinical models involving chemotherapy drugs including cisplatin, paclitaxel and docetaxel, psilocybin administered before chemotherapy protected sensory nerves and preserved tactile sensation.

The researchers reported protection even through repeated chemotherapy cycles, while chemotherapy maintained its antitumor activity. UT MD Anderson

That last point matters.

A neuroprotective drug would not be particularly useful if it also protected the tumor.

The preclinical evidence did not show that happening.

The team instead found something biologically elegant.

Psilocybin activated 5-HT2A serotonin receptors associated with a signaling cascade that helped maintain mitochondrial movement and distribution inside axons. UT MD Anderson

Why mitochondria matter

You probably remember mitochondria from biology class as:

“The powerhouse of the cell.”

That sentence has survived so many school exams it deserves Social Security.

But the simplified phrase hides something fascinating.

Neurons can stretch extraordinary distances.

A sensory nerve connecting your spinal cord to your toes has enormous energy demands along a long cellular highway.

Mitochondria must therefore be transported through these neurons to locations requiring energy.

Chemotherapy can disrupt that transportation system.

Think of the axon like Interstate 5 running from Seattle to San Diego.

Mitochondria are the fuel trucks.

Chemotherapy damages the highway and blocks the trucks.

Eventually, the distant neighborhoods start losing power.

Nerve endings deteriorate.

The MD Anderson work suggests psilocybin helped keep those mitochondrial trucks moving. Researchers identified involvement of a signaling network incorporating TrkB-Akt-PAK5-MAP2-KIF5B and remobilization of mitochondria otherwise anchored by syntaphilin. JOVE Visualizer

That is a radically different biological story than:

“Mushrooms make people see patterns.”

CATEGORY: THE BIOLOGY OF THE TRIP

What If Psychedelics Are Molecular Toolkits?

This is where psychedelic science becomes considerably more interesting than psychedelic culture.

The molecules do not know what category humans placed them in.

Psilocybin does not possess a tiny passport stamped:

PSYCHIATRY ONLY.

The 5-HT2A receptor exists within a much broader physiological network.

Researchers have increasingly investigated psychedelic compounds in relation to neuroplasticity, inflammation, pain and neuronal signaling.

The MD Anderson results push that investigation further toward neuroprotection.

And here comes the twist.

Researchers blocked the 5-HT2A pathway and lost the protective effect.

Then they used tabernanthalog, a non-hallucinogenic compound activating related receptor mechanisms.

Similar nerve protection appeared. UT MD Anderson

That raises one of the most important questions in psychedelic pharmacology:

How much therapeutic benefit requires the psychedelic experience itself?

The answer may differ by condition.

For psychotherapy, subjective experience might matter tremendously.

A profound alteration in perspective may contribute to psychological change.

For peripheral nerve protection?

The altered consciousness may be unnecessary.

Science could eventually separate pieces of psychedelic pharmacology into different medicines:

psychedelic experiences when the experience matters

and

non-psychedelic receptor-targeting compounds when it doesn't.

That is not the death of psychedelic medicine.

It is its maturation.

my TAKE

I have watched cannabis and psychedelic culture travel the same ridiculous road again and again.

First society says:

“There is nothing medically interesting here.”

Then researchers discover something medically interesting.

Then society says:

“Fine, but only for this one thing.”

Then another mechanism appears.

Then pharmaceutical companies arrive wearing lab coats and suddenly everybody starts acting like the molecule was born in a clean room.

I've spent roughly 25 years around cannabis and psychedelic culture, and if that experience has taught me anything, it is that culture usually discovers interesting phenomena before institutions understand the mechanisms—but culture is also spectacularly good at exaggerating those phenomena.

That distinction matters.

I've lived enough wild chapters—including Vegas—to know firsthand that intensity is not evidence.

A powerful experience can change your life.

It can also convince you that a hotel carpet is transmitting sacred geometry from another dimension.

Those are not necessarily the same category of information.

So when psychedelic research produces results this exciting, the correct response is neither:

“Magic mushrooms cure everything!”

nor:

“Psychedelics are drugs, therefore ignore the science.”

Both positions are intellectually lazy.

The better response is:

Interesting. Show me the mechanism. Show me replication. Show me humans.

And MD Anderson is moving toward that next step.

CATEGORY: FROM MOUSE TO HUMAN

NeuroGuard Is Where the Story Gets Serious

MD Anderson says the preclinical findings support an upcoming Phase 2 NeuroGuard trial, NCT07227909, evaluating psilocybin during chemotherapy in patients with multiple cancer types. UT MD Anderson

That does not mean psilocybin has been proven to prevent chemotherapy neuropathy in humans.

The distinction cannot be overstated.

Mouse neuroscience is extraordinarily useful.

Mice are also not miniature people with cheaper apartments.

Animal findings routinely fail to translate into clinical medicine because of differences in metabolism, dosing, disease complexity, biology and study conditions.

So the headline today is:

Psilocybin prevented chemotherapy-related nerve injury in preclinical models.

Not:

Psilocybin prevents chemotherapy neuropathy in cancer patients.

That second sentence remains a hypothesis awaiting clinical testing.

But the mechanistic evidence is strong enough to justify asking the question in humans.

That is exactly how science should work.

CATEGORY: PSYCHEDELIC POLICY

Meanwhile, New Zealand Quietly Opened Another Door

While researchers in Texas were examining psychedelic neuroprotection, another major psychedelic-development story emerged almost simultaneously.

On September 4, 2026, New Zealand's Ministry of Health announced that Medsafe had authorized two psychiatrists to prescribe pharmaceutical-grade MDMA as part of treatment programs for eligible adults with PTSD whose symptoms had not responded adequately to conventional treatment. Ministry of Health NZ

The distinction here is crucial.

New Zealand has not broadly approved MDMA as a medicine.

The authorization applies specifically to two approved psychiatrists operating under controlled protocols.

Patients must be adults, undergo comprehensive assessment and receive treatment within supervised clinical settings. The drug is not dispensed for home use. Ministry of Health NZ

New Zealand had previously granted limited permission for psychiatrists to prescribe medicinal psilocybin for treatment-resistant depression. The country now reports two clinicians approved to prescribe psilocybin and two approved to prescribe MDMA. Ministry of Health NZ

This might sound like bureaucratic trivia.

It isn't.

It demonstrates how psychedelic medicine may enter healthcare systems:

not through one gigantic legalization event,

but through dozens of narrow regulatory doors.

Australia opened one.

New Zealand opened another.

Clinical trials open others.

Medical systems rarely transform like fireworks.

They transform like termites.

Quietly.

Structurally.

Then one morning you notice the building has changed.

CATEGORY: REALITY CHECK

Psychedelic Media Has a Hype Problem

Now we need to ruin the party for five minutes.

A 2026 Scientific Reports study analyzed 6,805 media publications from 2017 through 2024 and found that psychedelic-treatment coverage used significantly more positive emotional language than coverage of established antidepressants, while antidepressant reporting contained comparatively more negative emotion and risk language. Nature

That should concern anyone who genuinely wants psychedelic medicine taken seriously.

Because hype is the enemy of legitimacy.

Every time somebody posts:

“PSILOCYBIN REWIRES YOUR BRAIN!”

without mentioning sample size, study design or uncertainty, another scientist develops hypertension.

The psychedelic renaissance already carries enormous historical baggage.

Overselling preliminary findings makes the field easier to dismiss.

Ironically, the most revolutionary thing psychedelic advocates can do right now may be remarkably boring:

Be accurate.

The chemotherapy-neuropathy study is exciting precisely because we do not need to exaggerate it.

The actual findings are strange enough.

CATEGORY: AI + MENTAL HEALTH

Another Revolution Is Making the Opposite Mistake

While psychedelic medicine struggles with hype, artificial intelligence is racing into mental health faster than our evidence base can keep up.

A new JAMA Pediatrics study published August 31 examined 39,761 students in Ontario, Canada.

Researchers found 21.1% reported using generative AI for emotional support or advice. Affective AI use was associated with greater emotional problems and clinically significant symptoms even after accounting for loneliness and perceived mattering. JAMA Network

But please notice the important scientific word:

associated.

The study was cross-sectional.

It cannot prove that AI caused the distress.

A very plausible alternative explanation is that distressed young people are simply more likely to seek emotional support from AI.

In other words:

AI might be the smoke detector rather than the fire.

Separate U.S. survey research published earlier this year found roughly 19.2% of adolescents and young adults aged 12–21 reported having used AI chatbots for mental-health advice in 2025, and most users had not disclosed that use to others. JAMA Network

That is not a niche phenomenon anymore.

It is infrastructure emerging accidentally.

Millions of young people are conducting psychological conversations with machines before regulation, clinical standards and social norms have caught up.

For SykoActive—and particularly any future mental-health technology we develop—that should be treated as both opportunity and warning.

AI can expand access.

AI can provide education.

AI can help people reflect, organize emotions and identify when professional support might be necessary.

But an empathetic interface is not automatically therapy.

Good language is not automatically good medicine.

And a chatbot saying the perfect thing at 2:13 AM does not magically create a healthcare system behind it.

The future needs both intelligence and boundaries.

CATEGORY: CONSCIOUSNESS

The Bigger Pattern: Medicine Is Moving From Labels Toward Mechanisms

Now connect the stories.

Psilocybin is moving beyond “psychedelic therapy.”

MDMA is moving from illicit-drug policy into highly controlled PTSD treatment.

AI is moving from productivity software into emotional relationships.

The borders between neuroscience, psychiatry, technology and consciousness are dissolving.

That does not mean everything becomes mystical.

It means our old categories were probably too crude.

For decades we've classified interventions according to their most obvious effects.

Psilocybin = hallucination.

MDMA = euphoria.

AI = information processing.

Meditation = relaxation.

But biology and consciousness are networks.

One receptor can participate in perception, cognition, plasticity and peripheral nerve function.

One technology can be a calculator, teacher, companion and psychological mirror.

One subjective experience can involve philosophy, neurochemistry, memory and identity simultaneously.

This is where I believe the next twenty years become extraordinary.

Not because we're discovering magical substances.

Because we're discovering that human beings are more interconnected systems than our institutions were designed to recognize.

Psychiatry studies the brain.

Oncology studies cancer.

Neurology studies nerves.

Computer science studies algorithms.

Spiritual traditions study subjective experience.

But the person living inside all these categories remains one organism.

Reality never agreed to our departmental boundaries.

THE BLOGGER PAPER PRINCIPLE

Don't Worship the Molecule. Study the Mechanism.

I love psychedelics.

I also distrust mythology surrounding psychedelics.

Those positions can coexist.

Psychedelic culture has sometimes treated molecules like spiritual personalities.

Pharmaceutical culture has sometimes treated molecules like intellectual property with side effects.

Both perspectives miss something.

A molecule is information interacting with biology.

The important questions are:

What receptors?

What pathways?

What tissues?

What timing?

What dose?

What risks?

What individual differences?

What therapeutic context?

What long-term consequences?

And most importantly:

Does the effect reproduce in humans?

If psilocybin ultimately prevents chemotherapy-induced nerve damage, that would represent something much larger than another psychedelic-treatment headline.

It would demonstrate that these molecules may contain pharmacological architectures we have barely mapped.

And if non-hallucinogenic derivatives can reproduce some effects, psychedelic research could eventually generate entire medicine classes where nobody ever trips at all.

That irony is beautiful.

After sixty years of cultural warfare over psychedelic consciousness, one of the field's important medical legacies might eventually be a drug that doesn't produce psychedelia.

Science has a sense of humor.

WHAT TO WATCH NEXT

Three developments deserve attention.

First, NeuroGuard. The transition from preclinical neuroprotection to human testing will determine whether this week's findings are genuinely transformative or simply another compelling animal result.

Second, non-hallucinogenic psychedelic-inspired compounds. Tabernanthalog's performance in the MD Anderson work strengthens the case for investigating therapeutic pathways independently from subjective psychedelic effects. Nature

Third, regulatory experimentation. New Zealand's narrowly controlled MDMA authorization demonstrates a model somewhere between blanket prohibition and conventional mass-market prescription approval. Ministry of Health NZ

Those three threads—mechanism, translation and regulation—will probably determine the next stage of psychedelic medicine far more than viral mushroom memes will.

FINAL THOUGHT

We spent decades asking whether psychedelic drugs could change consciousness.

Maybe that was only the opening question.

The deeper question is becoming:

What biological processes do these molecules influence that we never noticed because we were staring at the hallucinations?

The MD Anderson study does not prove psilocybin is a chemotherapy neuroprotectant for people.

But it does something intellectually important.

It expands the map.

And whenever science expands the map, assumptions start dying.

I know something about watching assumptions die.

I've spent years chasing ideas, building businesses, watching dreams explode spectacularly, picking through the wreckage, finding another road and trying to understand what all of it means.

Vegas teaches you quickly that bright lights can disguise terrible odds.

Psychedelic science should remember the same lesson.

Don't bet because the lights are pretty.

Bet because you've studied the numbers.

And right now, the numbers are interesting enough that I'm watching very closely.

Experience the trip.

Just don't confuse the trip with the entire destination.

— Gram Kracker
CEO, SykoActive